HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yoichi Hiasa Selected Research

Hepatitis B Core Antigens

12/2021The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial.
11/2021Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial.
11/2019Intranasal vaccination with HBs and HBc protein combined with carboxyl vinyl polymer induces strong neutralizing antibody, anti-HBs IgA, and IFNG response.
1/2018Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).
10/2012Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
8/2010Impaired dendritic cell functions disrupt antigen-specific adaptive immune responses in mice with nonalcoholic fatty liver disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yoichi Hiasa Research Topics

Disease

102Hepatocellular Carcinoma (Hepatoma)
10/2022 - 11/2003
45Neoplasms (Cancer)
01/2022 - 11/2003
23Fibrosis (Cirrhosis)
01/2022 - 03/2007
22Liver Cirrhosis (Hepatic Cirrhosis)
07/2021 - 06/2005
22Infections
01/2021 - 01/2006
20Non-alcoholic Fatty Liver Disease
05/2022 - 08/2010
16Chronic Hepatitis B
05/2022 - 02/2005
14Liver Neoplasms (Liver Cancer)
12/2021 - 03/2007
14Chronic Hepatitis C
02/2019 - 01/2004
13Liver Diseases (Liver Disease)
01/2021 - 04/2002
12Type 2 Diabetes Mellitus (MODY)
05/2022 - 01/2016
12Hypertension (High Blood Pressure)
03/2022 - 01/2016
11Neoplasm Metastasis (Metastasis)
01/2022 - 01/2010
10Inflammation (Inflammations)
03/2022 - 06/2011
10Hepatitis B
04/2021 - 07/2007
9Ascites
05/2022 - 04/2007
9Insulin Resistance
07/2019 - 01/2007
8Ulcerative Colitis
04/2022 - 01/2021
8Fatty Liver
10/2021 - 01/2014
8Alcoholic Fatty Liver
07/2021 - 08/2017
7Diabetic Nephropathies (Diabetic Nephropathy)
03/2018 - 01/2014
6Thrombocytopenia (Thrombopenia)
02/2020 - 03/2007
6Hepatitis
01/2020 - 02/2005
6Chronic Hepatitis (Chronic Active Hepatitis)
07/2019 - 04/2002
6Dyslipidemias (Dyslipidemia)
03/2018 - 01/2016
5Fatigue
06/2022 - 03/2011
5Diabetic Retinopathy (Retinopathy, Diabetic)
03/2018 - 01/2016
5Diabetic Neuropathies (Diabetic Neuropathy)
03/2018 - 01/2016
5Stroke (Strokes)
06/2017 - 01/2016
4Pancreatic Neoplasms (Pancreatic Cancer)
10/2021 - 01/2013
4Disease Progression
07/2021 - 06/2005
4Diabetes Mellitus
07/2019 - 05/2007
4Obesity
09/2018 - 03/2013
4Autoimmune Pancreatitis
02/2018 - 08/2011
4Biliary Liver Cirrhosis (Primary Biliary Cirrhosis)
04/2011 - 04/2002
3Varicose Veins (Varicose Vein)
10/2022 - 12/2011
3Portal Hypertension
10/2022 - 12/2011
3Hypothyroidism
06/2022 - 03/2019
3Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
01/2022 - 03/2012
3Thrombosis (Thrombus)
12/2021 - 02/2010
3Glucose Intolerance
10/2021 - 09/2009
3Sarcopenia
07/2021 - 12/2017
3Ischemic Stroke
03/2018 - 07/2016
3Hepatitis C
01/2018 - 04/2009
3Coronary Artery Disease (Coronary Atherosclerosis)
01/2017 - 01/2016

Drug/Important Bio-Agent (IBA)

24lenvatinibIBA
06/2022 - 01/2019
20AlbuminsIBA
10/2022 - 01/2009
18Antiviral Agents (Antivirals)IBA
01/2022 - 10/2007
15InterferonsIBA
01/2021 - 01/2004
14BilirubinIBA
01/2022 - 04/2009
14AntigensIBA
10/2021 - 04/2002
11Ribavirin (Virazole)FDA LinkGeneric
02/2019 - 05/2007
10alpha-Fetoproteins (alpha-Fetoprotein)IBA
10/2022 - 04/2006
10Proteins (Proteins, Gene)FDA Link
05/2022 - 11/2003
10Hepatitis B Surface Antigens (HBsAg)FDA Link
12/2021 - 01/2006
9Glucose (Dextrose)FDA LinkGeneric
05/2022 - 09/2009
9Biomarkers (Surrogate Marker)IBA
01/2022 - 06/2011
9VaccinesIBA
12/2021 - 07/2007
8Bevacizumab (Avastin)FDA Link
10/2022 - 01/2022
8atezolizumabIBA
10/2022 - 01/2022
8Sorafenib (BAY 43-9006)FDA Link
12/2021 - 04/2013
8Alanine Transaminase (SGPT)IBA
10/2021 - 03/2007
8CreatinineIBA
01/2020 - 01/2014
8Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
03/2018 - 01/2016
7C-Reactive ProteinIBA
10/2022 - 04/2013
7Messenger RNA (mRNA)IBA
01/2020 - 06/2005
7B-Cell Activating FactorIBA
01/2019 - 08/2011
6Hepatitis B Core AntigensIBA
12/2021 - 08/2010
6Insulin (Novolin)FDA Link
07/2019 - 04/2011
6Amino AcidsFDA Link
01/2017 - 06/2007
5Hemoglobins (Hemoglobin)IBA
04/2022 - 09/2010
5DNA (Deoxyribonucleic Acid)IBA
12/2021 - 02/2005
5Pharmaceutical PreparationsIBA
12/2021 - 01/2012
5Indicators and Reagents (Reagents)IBA
07/2021 - 01/2014
5CytokinesIBA
01/2021 - 08/2010
4Aspartate Aminotransferases (Aspartate Transaminase)IBA
05/2022 - 02/2011
4Serum AlbuminIBA
04/2022 - 03/2011
4Palmitic Acid (Hexadecanoic Acid)IBA
01/2021 - 11/2012
4Tyrosine Kinase InhibitorsIBA
01/2020 - 01/2017
4Branched-Chain Amino AcidsIBA
07/2019 - 04/2010
4Protein Kinases (Protein Kinase)IBA
01/2019 - 11/2003
4Lamivudine (Epivir)FDA Link
10/2014 - 02/2005
4RNA (Ribonucleic Acid)IBA
01/2009 - 06/2005
3ORALIT (ORS)IBA
01/2022 - 02/2018
3InterleukinsIBA
01/2022 - 10/2011
3regorafenibIBA
08/2021 - 01/2019
3Carbon Tetrachloride (Tetrachloromethane)IBA
07/2021 - 01/2017
3CollagenIBA
03/2021 - 01/2012
3SofosbuvirIBA
01/2021 - 01/2017
3HDL CholesterolIBA
01/2020 - 01/2014
3Triglycerides (Triacylglycerol)IBA
01/2020 - 01/2014
3AdipokinesIBA
01/2019 - 10/2011
3acarboxyprothrombin (PIVKA)IBA
01/2017 - 04/2013

Therapy/Procedure

61Therapeutics
06/2022 - 04/2002
22Radiofrequency Ablation
07/2021 - 12/2006
9Drug Therapy (Chemotherapy)
10/2021 - 01/2006
6Splenectomy
12/2020 - 03/2007
5Liver Transplantation
04/2020 - 03/2007
4Immunotherapy
10/2022 - 10/2005
3Punctures
03/2019 - 08/2009